AbbVie reports Q4 adjusted EPS $2.71, consensus $2.65

Reports Q4 revenue $16.62B, consensus $16.42B. “2025 was another outstanding year for AbbVie (ABBV). We delivered record net sales in just the second full year following the U.S. Humira loss of exclusivity, underscoring the strength of our diversified growth platform. We also advanced promising new treatments for patients while enhancing the breadth and depth of our pipeline with strategic investments,” said Robert A. Michael, chairman and chief executive officer, AbbVie. “Based on our strong fundamentals, we expect another year of robust growth in 2026. This momentum combined with our investments in innovation position AbbVie for long-term success.”